Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Halozyme and Oruka sign agreement for Hypercon technology
Oruka has licensed the Halozyme technology for use with its lead programme, ORKA-001, which is in development to treat psoriasis and related inflammatory conditions, and up to one
Oruka has licensed the Halozyme technology for use with its lead programme, ORKA-001, which is in development to treat psoriasis and related inflammatory conditions, and up to one
The therapy is approved by the US Food and Drug Administration (FDA) for adult patients with relapsed or refractory Stage I-III cutaneous T-cell lymphoma (CTCL) following at least one prior systemic treatment. The
Following a successful tender offer and subsequent merger, the companies announced the completion of the transaction, making Terns a wholly owned subsidiary of MSD. The US Food and
Langlara is cleared for use in adults and children with type 1 diabetes mellitus (T1DM), as well as adults with type 2 diabetes mellitus (T2DM). The FDA’s decision
The financing includes a $43m extension led by 8VC, with participation from existing investors BioAdvance, Benjamin Franklin Technology Partners, DCVC Bio, Gaingels, Hatch BioFund and Modi Ventures. New
The therapy is approved as an add-on to diet, specifically for adults with FCS whose triglyceride levels remain high despite standard triglyceride-lowering treatments. The approval marks an expansion
The Ozempic oral pill, approved by the Food and Drug Administration (FDA), offers an option for adults with type 2 diabetes to manage blood sugar and cardiovascular risk
Auvelity is a first-in-class therapy targeting both N-methyl D-aspartate (NMDA) and sigma-1 receptors for this indication. The FDA’s decision is based on results from the Phase III ADVANCE-1
The acquisition aims to strengthen LEO Pharma’s capabilities while leveraging Replay’s high payload herpes simplex virus (HSV) delivery vector. It is set to expand LEO Pharma’s pipeline in
The designation recognises the potential of RTx-015 to address significant unmet medical needs in patients with severe retinal degeneration. It advances the therapy’s regulatory support following a regenerative